Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 28, 2016; 8(24): 1012-1018
Published online Aug 28, 2016. doi: 10.4254/wjh.v8.i24.1012
Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension
Alberto Ferrarese, Alberto Zanetto, Giacomo Germani, Patrizia Burra, Marco Senzolo
Alberto Ferrarese, Alberto Zanetto, Giacomo Germani, Patrizia Burra, Marco Senzolo, Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, 35128 Padua, Italy
Author contributions: Ferrarese A wrote and reviewed the manuscript; Zanetto A and Germani G edited the manuscript; Burra P and Senzolo M supervised, drafted and reviewed the manuscript.
Conflict-of-interest statement: The authors do not have anything to disclose about this paper. The authors did not receive any funding for producing the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Marco Senzolo, MD, PhD, Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, via Giustiniani 2, 35128 Padua, Italy. marcosenzolo@hotmail.com
Telephone: +39-04-98218726 Fax: +39-04-98218727
Received: April 30, 2016
Peer-review started: May 3, 2016
First decision: June 17, 2016
Revised: July 1, 2016
Accepted: July 14, 2016
Article in press: July 18, 2016
Published online: August 28, 2016
Processing time: 117 Days and 9.7 Hours
Core Tip

Core tip: In this review, we’ve critically analyzed the recent evidence on the role played by non-selective beta blockers in patients with decompensated liver disease.